Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07220733 · ClinicalTrials.gov registry record · Phase 1

Safety and Feasibility of a Self-Balancing Exoskeleton for Rehabilitation in the Thoracic Surgical Intensive Care Unit: a Pilot Trial

A Phase 1 study of Critical Illness and Thoracic Surgery, sponsored by Wandercraft.

Recruiting
Registry status
Phase 1
Development phase
5
Enrollment target
1
Study location

NCT07220733 is a Phase 1 study of Critical Illness and Thoracic Surgery that is actively recruiting participants, run by Wandercraft. The registered enrollment target is 5 participants, below the 3,138-participant average among 91 other Critical Illness trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07220733, a Phase 1 study of Critical Illness and Thoracic Surgery, is actively recruiting participants, sponsored by Wandercraft.

RECRUITING
Registry status
Phase 1
Development phase
5 participants
Enrollment target
1
Study location

Study Summary

Patients admitted to the Intensive Care Unit (ICU) after thoracic surgery often experience complications related to immobility, such as muscle weakness, pulmonary issues, and longer recovery times. Early mobilization has been shown to improve outcomes, but its implementation is often limited by patient fragility and staff resources. This study will test the safety and feasibility of using the Atalante X, a self-balancing exoskeleton, in the Thoracic Surgical ICU at Brigham and Women's Hospital. The exoskeleton is designed to support patients in standing and walking, even if they have limited strength or balance, thereby reducing the physical burden on healthcare staff and increasing patient mobility. Eligible participants are adults recovering from thoracic surgery, who are debilitated (Johns Hopkins Highest Level of Mobility scale ≤ 5). Each participant will undergo up to 2-3 exoskeleton sessions per week for a maximum of 2 weeks. Sessions will be personalized, with progressive standing time and walking depending on patient tolerance. The primary goal is to evaluate the safety of exoskeleton use, measured by adverse events such as skin lesions, cardiovascular instability, or accidental device-related issues. The secondary goals are to evaluate: Feasibility (ability to deliver sessions as planned, duration of standing/walking, level of assistance needed), Usability (patient and staff satisfaction, ease of donning/doffing, staff workload), and Preliminary effectiveness (improvement in mobility scores at discharge). Results will provide early insights into whether robotic exoskeletons can be safely integrated into ICU rehabilitation programs after thoracic surgery.

Interventions

  • DEVICE Self-balancing robotic exoskeleton (Atalante X)

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2025-10
Est. Completion 2026-02
Phase Phase 1

Sponsor

Wandercraft

5 total trials

What the Registry Record Tells You About NCT07220733

The ClinicalTrials.gov registry entry for NCT07220733 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,138-participant average among 91 other Critical Illness trials with a reported enrollment target (100% lower). The listed sponsor is Wandercraft, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Critical Illness appearing as the primary indexed condition, and to 1 intervention - of which Self-balancing robotic exoskeleton (Atalante X) is the first listed.

NCT07220733 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07220733 about?

NCT07220733 is a clinical study titled "Safety and Feasibility of a Self-Balancing Exoskeleton for Rehabilitation in the Thoracic Surgical Intensive Care Unit: a Pilot Trial". Patients admitted to the Intensive Care Unit (ICU) after thoracic surgery often experience complications related to immobility, such as muscle weakness, pulmonary issues, and longer recovery times. Early mobilization has been shown to improve outcomes, but its implementation is often limited by pati...

What is the current status of trial NCT07220733?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2025-10. Estimated completion is 2026-02.

What conditions does trial NCT07220733 study?

This clinical trial studies the following conditions: Critical Illness, Thoracic Surgery, Post Operative Complication.

What interventions are being tested in trial NCT07220733?

The interventions under investigation include: Self-balancing robotic exoskeleton (Atalante X) (DEVICE).

Who is sponsoring clinical trial NCT07220733?

This trial is sponsored by Wandercraft, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07220733 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Critical Illness

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.